Related Experiment Video
Updated: Mar 17, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine
Ji-Ye Yin1,2,3, Xi Li1,2,3, Hong-Hao Zhou1,2,3
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P.R. China.
Abstract:
Lung cancer is one of the leading causes of cancer-related death in the world. Platinum-based chemotherapy is the first-line treatment for non-small-cell lung cancer (NSCLC), however, the therapeutic efficiency varies remarkably among individuals. A large number of pharmacogenomics studies aimed to identify genetic variations which can be used to predict platinum response. Those studies are leading NSCLC treatment to the new era of precision medicine. In the current review, we provided a comprehensive update on the main recent findings of genetic variations which can be used to predict platinum sensitivity in the NSCLC patients.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetics and Pharmacogenomics: Overview

